Peter Linsley Email

CSO . Regulus Therapeutics

Current Roles

Employees:
41
Revenue:
$7.5M
About
Regulus Therapeutics is a biopharmaceutical company created to discover, develop and commercialize microRNA therapeutics. Formed as a joint venture between Isis – a pioneer in oligonucleotide drug technologies and a leader in the field of antisense therapeutics, and Alnylam – a leader in the field of RNAi therapeutics, Regulus intends to address therapeutic opportunities that arise from abnormal expression or mutations in microRNAs. Since microRNAs regulate the expression of broad networks of genes and biological pathways, microRNA therapeutics define a new strategy to target multiple points on disease pathways. Regulus has assembled world-class scientists and the foremost authorities in the field of microRNA research to lead this new venture. In addition, Regulus has been formed combining the leading capabilities and intellectual property estates of its two parent companies. Thus, in Regulus, its founders have created the leading microRNA therapeutics company, a company that will translate one of the most important new frontiers in modern biology into an entirely new approach for innovative medicines by targeting the pathways of human disease with microRNA therapeutics.
Regulus Therapeutics Address
4224 Campus Point Court
San Diego, CA
United States
Regulus Therapeutics Email

Past Companies

Regulus TherapeuticsCSO
MerckExec. Dir. Cancer Biol.

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.